Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17261
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSherry, Norelle-
dc.contributor.authorHowden, Benjamin P-
dc.date2018-03-15-
dc.date.accessioned2018-03-21T05:17:25Z-
dc.date.available2018-03-21T05:17:25Z-
dc.date.issued2018-
dc.identifier.citationExpert review of anti-infective therapy 2018; 16(4): 289-306-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/17261-
dc.description.abstractMultidrug-resistant (MDR) and extensively-drug-resistant (XDR) Gram-negative bacteria have emerged as a major threat to human health globally. This has resulted in the "re-discovery" of some older antimicrobials and development of new agents, however resistance has also rapidly emerged to these agents. Areas Covered: Here we describe recent developments in resistance to three of the most important last-line antimicrobials for treatment of MDR and XDR Gram negatives: fosfomycin, colistin and ceftazidime-avibactam. Expert Commentary: A key challenge for microbiologists and clinicians using these agents for treating patients with MDR and XDR Gram negative infections is the need to ensure appropriate reference methods are being used to test susceptibility to these agents, especially colistin and fosfomycin. These methods are not available in all laboratories meaning accurate results are either delayed, or potentially inaccurate as non-reference methods are employed. Combination therapy for MDR and XDR Gram negatives is likely to become more common, and future studies should focus on the clinical effects of monotherapy vs combination therapy, as well as validation of synergy testing methods. Effective national and international surveillance systems to detect and respond to resistance to these last line agents are also critical.-
dc.language.isoeng-
dc.subjectantimicrobial resistance-
dc.subjectceftazidime-avibactam-
dc.subjectcolistin-
dc.subjectfosfomycin-
dc.subjectresistance detection-
dc.subjectresistance mechanisms-
dc.titleEmerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam - epidemiology, laboratory detection and treatment implications.-
dc.typeJournal Article-
dc.identifier.journaltitleExpert review of anti-infective therapy-
dc.identifier.affiliationAntimicrobial Reference and Research Unit, Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia-
dc.identifier.affiliationDepartment of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.doi10.1080/14787210.2018.1453807-
dc.identifier.pubmedid29543500-
dc.type.austinJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptInfectious Diseases-
crisitem.author.deptMicrobiology-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.